Free Trial

Genmab A/S (GMAB) Earnings Date, Estimates & Call Transcripts

Genmab A/S logo
$20.59 -0.59 (-2.79%)
(As of 11/15/2024 ET)

Genmab A/S Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 12Estimated
Actual EPS
(Nov. 6)
$0.29 Missed By -$0.03
Consensus EPS
(Nov. 6)
$0.32

Genmab A/S issued Q3 2024 earnings on November 6, 2024, reporting an EPS of $0.29, which missed the consensus estimate of $0.32 by $0.03. Quarterly revenue was reported to be $816.10 million, below analyst estimates of $838.20 million. With a trailing EPS of $1.03 and a P/E Ratio of 19.99, Genmab A/S's earnings are expected to grow 14.84% next year, from $1.28 to $1.47 per share.

GMAB Upcoming Earnings

Genmab A/S's next earnings date is estimated for Wednesday, February 12, 2025, based off prior year's reporting schedules.

Get Genmab A/S Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

GMAB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

GMAB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Genmab A/S Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243$0.14$0.26$0.18
Q2 20243$0.26$0.34$0.30
Q3 20243$0.27$0.34$0.30
Q4 20243$0.34$0.41$0.38
FY 202412$1.01$1.35$1.16

Genmab A/S Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/12/2025
(Estimated)
------- 
11/6/2024Q3 2024$0.32$0.29 -$0.03$0.29$838.20M$816.10M    
8/8/2024Q2 2024$0.29$0.22 -$0.07$0.13$734.60M$779.50M
5/2/2024Q1 2024$0.16$0.16-$0.03$594.23M$603.30M    
2/14/2024Q4 2023$0.34$0.36+$0.02$0.58$678.14M$675.29M    
11/7/2023Q3 2023$0.34$0.47+$0.13$0.47$657.79M$692.80M    
8/3/2023Q2 2023$0.31$0.30 -$0.01$0.30$618.77M$613.43M    
5/10/2023Q1 2023$0.09$0.05 -$0.04$0.05$417.27M$411.37M    
2/22/2023Q4 2022$0.35$0.12 -$0.23$0.12$634.17M$717.54M    

Genmab A/S Earnings - Frequently Asked Questions

Genmab A/S has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 12th, 2025 based off last year's report dates. Learn more on GMAB's earnings history.

Genmab A/S updated its FY 2024 earnings guidance on Wednesday, November, 6th. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

In the previous quarter, Genmab A/S (NASDAQ:GMAB) missed the analysts' consensus estimate of $0.32 by $0.03 with a reported earnings per share (EPS) of $0.29. Learn more on analysts' earnings estimate vs. GMAB's actual earnings.

The conference call for Genmab A/S's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Genmab A/S's latest earnings report can be read online.
Read Transcript

Genmab A/S (NASDAQ:GMAB) has a recorded annual revenue of $2.39 billion.

Genmab A/S (NASDAQ:GMAB) has a recorded net income of $631.91 million. GMAB has generated $1.03 earnings per share over the last four quarters.

Genmab A/S (NASDAQ:GMAB) has a trailing price-to-earnings ratio of 19.99 and a forward price-to-earnings ratio of 16.09. The price/earnings-to-growth ratio is 0.64.

Genmab A/S's earnings are expected to grow from $1.28 per share to $1.47 per share in the next year, which is a 14.84% increase.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:GMAB) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners